Cite
HARVARD Citation
Subbiah, V. et al. (2020). Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet oncology. 21 (9), pp. 1234-1243. [Online].